345275243168ENSG00000170509ENSMUSG00000034528Q7Z5P4Q8VCR2NM_178135NM_001136230NM_001163486NM_198030NP_001129702NP_835236NP_001156958NP_93214717β-Hydroxysteroid dehydrogenase type 13 also known as 17β-HSD type 13 is an enzyme that in humans is encoded by the HSD17B13 gene.

[5][6] 17β-HSD13 is significantly up-regulated in the liver of patients with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis.

[7] In 2023 the first potent and selective HSD17B13 inhibitor, BI-3231, was reported.

[8] The inhibitor meets the quality criteria of a 'Donated Chemical Probe' as defined by the Structural Genomics Consortium.

[9] This enzyme-related article is a stub.